These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 35012940)
21. [Discovery of a new mutation in MYOD1 characterizes a subset of aggressive embryonal rhabdomyosarcoma partnering with mutations of the PI3K-AKT pathway]. Orbach D Bull Cancer; 2014 Sep; 101(9):776-7. PubMed ID: 25295632 [No Abstract] [Full Text] [Related]
22. A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases. Alaggio R; Zhang L; Sung YS; Huang SC; Chen CL; Bisogno G; Zin A; Agaram NP; LaQuaglia MP; Wexler LH; Antonescu CR Am J Surg Pathol; 2016 Feb; 40(2):224-35. PubMed ID: 26501226 [TBL] [Abstract][Full Text] [Related]
23. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Weigelt B; Warne PH; Downward J Oncogene; 2011 Jul; 30(29):3222-33. PubMed ID: 21358673 [TBL] [Abstract][Full Text] [Related]
24. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Rubinstein MM; Hyman DM; Caird I; Won H; Soldan K; Seier K; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Hensley ML; Troso-Sandoval T; Sabbatini P; Guillen J; Selcuklu SD; Zimel C; Torrisi J; Aghajanian C; Makker V Cancer; 2020 Mar; 126(6):1274-1282. PubMed ID: 31880826 [TBL] [Abstract][Full Text] [Related]
25. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828 [TBL] [Abstract][Full Text] [Related]
26. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Stemke-Hale K; Gonzalez-Angulo AM; Lluch A; Neve RM; Kuo WL; Davies M; Carey M; Hu Z; Guan Y; Sahin A; Symmans WF; Pusztai L; Nolden LK; Horlings H; Berns K; Hung MC; van de Vijver MJ; Valero V; Gray JW; Bernards R; Mills GB; Hennessy BT Cancer Res; 2008 Aug; 68(15):6084-91. PubMed ID: 18676830 [TBL] [Abstract][Full Text] [Related]
27. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358 [TBL] [Abstract][Full Text] [Related]
28. [Spindle cell/sclerosing rhabdomyosarcoma: a clinicopathological study of 20 cases]. Yang L; Zhang HJ; Yang SJ Zhonghua Bing Li Xue Za Zhi; 2020 Apr; 49(4):336-342. PubMed ID: 32268670 [No Abstract] [Full Text] [Related]
29. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines. Yeung Y; Lau DK; Chionh F; Tran H; Tse JWT; Weickhardt AJ; Nikfarjam M; Scott AM; Tebbutt NC; Mariadason JM Mol Oncol; 2017 Sep; 11(9):1130-1142. PubMed ID: 28544747 [TBL] [Abstract][Full Text] [Related]
30. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer. De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101 [TBL] [Abstract][Full Text] [Related]
32. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319 [TBL] [Abstract][Full Text] [Related]
33. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers. Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759 [TBL] [Abstract][Full Text] [Related]
34. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cheung LW; Hennessy BT; Li J; Yu S; Myers AP; Djordjevic B; Lu Y; Stemke-Hale K; Dyer MD; Zhang F; Ju Z; Cantley LC; Scherer SE; Liang H; Lu KH; Broaddus RR; Mills GB Cancer Discov; 2011 Jul; 1(2):170-85. PubMed ID: 21984976 [TBL] [Abstract][Full Text] [Related]